BTG to commercialise sleep disorder sensor:
This article was originally published in Clinica
The international subsidiary of UK technology transfer company BTG is looking for a partner to commercialise a non-invasive monitor for respiratory disorders such as sleep apnoea and sudden infant death syndrome (SIDS). The monitor uses a fibre-optic coupler sensor which is placed on a person's pulse point. This allows a single sensor to detect heartbeat and respiration rate at the same time. A second sensor can be used to monitor blood pressure. To detect SIDS a single fibre-optic cable could be incorporated into a thin mattress, says BTG. Unlike most infant apnoea monitors, it would not need to be connected to the baby. Software associated with the sensor can identify changes in breathing while eliminating the effects of body movements.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.